| 1 |
34944900 | Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer. | 2021 Dec 14 |
1 |
| 2 |
32942617 | HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line. | 2020 Sep 15 |
3 |
| 3 |
32988919 | Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. | 2020 Oct |
1 |
| 4 |
31477168 | A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). | 2019 Sep 2 |
1 |
| 5 |
29476008 | Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. | 2018 Mar 13 |
1 |
| 6 |
27942916 | Synergistic disruption of ERĪ±/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells. | 2017 Jan |
3 |
| 7 |
29069787 | Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. | 2017 Sep 22 |
1 |
| 8 |
27491481 | Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. | 2016 Oct |
3 |
| 9 |
26015514 | Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. | 2015 Sep 1 |
1 |
| 10 |
26557906 | Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib. | 2015 Nov |
6 |
| 11 |
24352641 | Managing breast cancers with low estrogen receptor and HER2 by drugging both. | 2014 Feb 1 |
1 |
| 12 |
23233650 | An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). | 2013 Apr |
1 |
| 13 |
23706161 | OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2. | 2013 May 24 |
2 |
| 14 |
22686613 | Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. | 2012 Jun 18 |
2 |
| 15 |
20179226 | Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. | 2010 Mar 1 |
6 |
| 16 |
20179241 | Does lapatinib work against HER2-negative breast cancers? | 2010 Mar 1 |
1 |
| 17 |
16682622 | A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. | 2006 May 16 |
7 |
| 18 |
15665275 | The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. | 2005 Jan 1 |
4 |